Sofinnova Investments’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$94.9M Buy
160,070
+2,429
+2% +$1.21M 3.61% 7
2025
Q4
$76.8M Sell
157,641
-32,985
-17% -$15.4M 3.31% 6
2025
Q3
$79.9M Buy
190,626
+72,113
+61% +$24.3M 4.37% 4
2025
Q2
$34.1M Buy
+118,513
New +$35.4M 2.08% 18
2023
Q1
Sell
-89,207
Closed -$24.8M 62
2022
Q4
$24.8M Sell
89,207
-58,357
-40% -$14.7M 1.47% 17
2022
Q3
$30.9M Buy
147,564
+41,185
+39% +$9.21M 1.8% 14
2022
Q2
$25.1M Sell
106,379
-92,804
-47% -$18.9M 2.09% 12
2022
Q1
$35.7M Buy
199,183
+69,429
+54% +$13.2M 2.71% 9
2021
Q4
$28M Sell
129,754
-92,340
-42% -$18.1M 1.64% 14
2021
Q3
$41M Buy
222,094
+6,009
+3% +$1.18M 2.43% 9
2021
Q2
$38.8M Buy
216,085
+1,031
+0.5% +$196K 2.23% 9
2021
Q1
$36M Sell
215,054
-132,847
-38% -$22.2M 2.16% 11
2020
Q4
$52.8M Buy
347,901
+26,942
+8% +$3.54M 3.14% 5
2020
Q3
$32.4M Buy
320,959
+16,397
+5% +$1.8M 2.4% 9
2020
Q2
$36.9M Buy
304,562
+71,003
+30% +$7.99M 2.32% 8
2020
Q1
$22.1M Buy
233,559
+44,914
+24% +$4.27M 2.05% 12
2019
Q4
$16.6M Sell
188,645
-5,369
-3% -$472K 1.2% 18
2019
Q3
$15.5M Buy
+194,014
New +$15.6M 1.4% 22

Other funds holding UTHR

Sofinnova Investments's UTHR Position: Q1 2026 in Review

Sofinnova Investments increased its United Therapeutics (UTHR) stake by 1.5% in Q1 2026, buying an estimated $1.21M and bringing the position to 160,070 shares worth $94.9M. The position accounts for 3.61% of the portfolio, ranked #7.

Sofinnova Investments first reported a position in UTHR in Q3 2019 and has held it in 18 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Sofinnova Investments held 160,070 shares of United Therapeutics worth $94.9M as of Q1 2026.
  • Sofinnova Investments bought 2,429 United Therapeutics shares in Q1 2026, an estimated $1.21M.
  • United Therapeutics made up 3.61% of Sofinnova Investments's portfolio in Q1 2026, its #7 holding.
  • Sofinnova Investments first reported a position in United Therapeutics in Q3 2019 and has held it in 18 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.